Cation Selective Transporters in the Intestine Contribute to the Glucose-Lowering Effect of Metformin by Fanizza, Frank
CATION	SELECTIVE	TRANSPORTERS	IN	THE	INTESTINE	CONTRIBUTE	TO	THE	GLUCOSE-	LOWERING	EFFECT	OF	METFORMIN	Frank	Fanizza,	PharmD	Candidate	UNC	Eshelman	School	of	Pharmacy	Honors	Program		
	
Figure 1:  Chemical 
Structure of Metformin	
ABSTRACT 
Metformin is the most widely prescribed anti-hyperglycemic agent for Type 2 Diabetes 
Mellitus (T2DM). Despite its frequent use, the intestinal absorption mechanism of this 
orally administered drug is still under investigation, and it is not known why up to 36% of 
diabetics on metformin therapy are nonresponsive. Previous studies in the Thakker 
laboratory have demonstrated that organic cation transporters (Octs) mediate metformin 
intestinal absorption and influence its pharmacokinetics in mice. Using a diabetic mouse 
model of T2DM, this study aims to demonstrate that Octs enhance the contribution of the 
intestine to the overall glucose-lowering effects of metformin. Mice were administered 
metformin orally in the presence and absence of the cation-selective transporter inhibitor, 
pentamidine, and blood glucose levels were measured using an OneTouch Ultra 
glucometer.  Our data suggest that intestinal cation-selective transporters facilitate the 
glucose-lowering effect of oral metformin, and that inhibition of these transporters by 
pentamidine diminishes the glucose-lowering efficacy of this drug. Thus, the intestine 
may play a role in the pharmacodynamic effects of metformin and contribute to the 
glucose-lowering response.  
 
INTRODUCTION 
Metformin and Type 2 Diabetes Mellitus 
 Metformin is an anti-diabetic drug widely used to treat T2DM.  It is currently the 
most prescribed anti-hyperglycemic medication for diabetes in the United States.1 T2DM 
is a chronic disease characterized by hyperglycemia and insulin resistance.  Metformin 
has effects on multiple parts of the body including the liver, intestine, and skeletal 
muscles. Studies show that metformin decreases gluconeogenesis in the liver and 
reduces glucose transport into the intestine while increasing glucose consumption.  It 
also increases insulin sensitivity in skeletal muscle, which improves glucose utilization.  
All these actions help to reduce blood glucose levels in the body.2  
Metformin Pharmacokinetics 
 Metformin is a positively charged molecule at all 
physiological pH values (Figure 1).  As a hydrophilic and 
cationic molecule, paracellular diffusion would be thought of 
as its primary mode of transport across epithelial cells.  
CATION	SELECTIVE	TRANSPORTERS	IN	THE	INTESTINE	CONTRIBUTE	TO	THE	GLUCOSE-	LOWERING	EFFECT	OF	METFORMIN	Frank	Fanizza,	PharmD	Candidate	UNC	Eshelman	School	of	Pharmacy	Honors	Program		
	
Figure 2:  Sponge Hypothesis which states that the cycling 
of metformin between the gut lumen and enterocytes as 
metformin dose travels distally through the intestine leads to 
efficient absorption by increasing opportunities to access the 
paracellular space. 
However, due to the restrictive nature of tight junctions and the limited surface area they 
provide in intestinal epithelial cells, paracellular diffusion would lead to a low 
bioavailability.  However, metformin has a bioavailability ranging from 40-60%, which is 
higher than molecules with similar characteristics.  Mannitol, which is also a hydrophilic 
and charged molecule in the intestine with a similar molecular weight as metformin, 
undergoes paracellular diffusion to enter the systemic circulation.  However, unlike 
metformin, mannitol only has an oral bioavailability of 16%.3-4 This discrepancy in 
bioavailability led to the idea that metformin may have a different mechanism of 
absorption than paracellular diffusion.  The Thakker Laboratory has done extensive work 
over the last several years to uncover the pharmacokinetic properties of metformin and 
how it is absorbed into the body. A former student of the Thakker laboratory elucidated 
the transport kinetics of metformin using the Caco-2 transwell intestinal cell model, and 
uncovered that metformin is efficiently transported across the apical membrane of the 
Caco-2 cell monolayer in either direction, while basolateral efflux is poor.5 This lack of 
basolateral efflux led to the hypothesis that metformin accumulates in the Caco-2 cells, 
and 3-compartmental modeling of these data suggested that metformin transport 
primarily occurs (>90%) via paracellular diffusion.  This study led to the development of 
the “Sponge Hypothesis” which states that as metformin travels along the 
gastrointestinal tract, some will be absorbed via paracellular diffusion through tight 
junctions and some will be taken up via cation-selective transporters into the epithelial 
cells of the small intestine.  Since there is poor basolateral efflux of metformin, the drug 
will accumulate in the intestinal cells, and then efflux back into the lumen of the small 
intestine.  While in the lumen of the small intestine, metformin can then undergo further 
absorption via paracellular 
diffusion. The key features of this 
hypothesis are that metformin has 
the ability to be taken up directly 
at the apical side of the intestinal 
epithelial cells, but cannot pass 
through the basolateral side of the 
cells.  The majority of metformin 




Figure 3:  Chemical Structure of Pentamidine	
		
Figure 4:  Area Under the Curve of Metformin 
Plasma Concentrations in the Presence and 
Absence of the Transporter Inhibitor 
Pentamidine. After oral administration of metformin 
with and without pentamidine, metformin plasma 
concentrations were significantly lower in the 
presence of pentamidine (p<0.01). 
diffusion, which is enhanced by the ability of metformin to efflux out of the intestinal cells 
and re-enter the intestinal lumen (Figure 2).5 The individual cation-selective transporters 
that facilitate metformin uptake in Caco-2 cells were recently identified by the Thakker 
group, and include the plasma membrane monoamine transporter, organic cation 
transporter 1, serotonin transporter, and choline transporter.6 
 In addition to unveiling the transporters involved in the uptake of metformin, 
recent studies in the Thakker 
laboratory have also shown that 
chemical inhibition of these 
transporters reduces systemic 
absorption of metformin in vitro and in 
vivo.7 Pentamidine, which is a positively charged molecule at physiological pH, has the 
ability to inhibit all four transporters 
involved in metformin uptake by Caco-2 
cells (Figure 3).  A study by a former 
graduate student of the Thakker 
laboratory on wild type mice showed 
that the plasma concentrations of 
metformin were significantly reduced 
when metformin was administered in 
the presence of the pan transporter 
inhibitor, pentamidine (Figure 4). Based 
on these data, this study aims to 
determine if intestinal cation-selective 
transporters play a role in the pharmacological effects of metformin in addition to 
influencing its pharmacokinetics.   
        
Hypothesis:  Intestinal apical transporters of metformin enhance its glucose-lowering 
effect.  
Specific Aim:  Establish that transporters increase the intestinal absorption of metformin 




 B6.BKS(D)-Leprdb/J (Db/Db) mice are a strain of mouse which is homozygous for 
a defective Lepr gene.  The Lepr gene codes for the leptin receptor, which is necessary 
for the feeling of satiety and fullness.  This defect leads to the development of diabetes 
mellitus and it has been shown that Db/Db mice are a good model for T2DM seen in 
humans.  Db/Db mice become obese near 3-4 weeks of age.  Whereas a non-diabetic 
mouse will have a fasting plasma glucose (FPG) around 150 mg/dL, a Db/Db mouse will 
have an average FPG level anywhere between 300-500 mg/dL.8 All mice were fasted for 
a total of four hours prior to receiving experimental procedures. Fasting was continued 
throughout the duration of each experiment and the mice only had access to water.   
Oral Gavage Studies 
 Twelve Db/Db mice were divided into 3 groups (n=4/group).  Group 1 (control 
group) received distilled water at time 0 followed by distilled water 15 min later. Group 2 
received distilled water at time 0 and metformin (450 mg/kg) 15 min later, and Group 3 
received pentamidine (3.4 mg/kg) at time 0 followed by metformin (450mg/kg) plus 
pentamidine (3.4 mg/kg) 15 min later. All treatments were administered via oral gavage 
at 5 µL/g. Blood samples were collected via the tail vein before the treatment (time 0) 
and then at 0.25, 0.5, 1, 2, 3, 4, 5, and 6 hours post treatment.  Blood glucose levels 
were measured with an OneTouch Ultra glucometer. 
 
Statistical Analysis 
 Blood glucose levels at each time point were compared among all three groups 
using a two-way ANOVA. A one-way ANOVA was used to compare total blood glucose 
concentrations between Groups 2 and 3 (i.e., area under the metformin effect curve).  
 
Results 
Oral Gavage Studies 
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Figure 6:  Area Under Effect Curve of 
Blood Glucose Over 6 Hours in Db/Db 
Mice. Orally administered metformin  
significantly reduced total blood glucose 
concentrations over 6 hours in db/db mice 
compared to the control (distilled water, 
p<0.05). Co-administered pentamidine 
attenuated metformin effect on blood glucose 
levels. 	
	
Figure 5:  Fraction of Blood Glucose vs Time in 
Db/Db Mice. Orally administered metformin 
significantly decreased blood glucose levels over 1 
to 6 hours compared to the control (distilled water).  
Co-administered pentamidine attenuated metformin 
effect on glucose levels, which was significant at 1 
and 3 hours post treatment (p<0.05). 
* p<0.05, **p<0.01, ***p<0.001 	
 In mice which received distilled 
water at time 0 and metformin (450 
mg/kg) 15 min later (i.e., Group 2), orally 
administered metformin significantly 
decreased blood glucose levels over 1 to 
6 hours compared to control mice 
(Group 1) (p<0.01 at 1, 2, 4, 5 and 6 hr; 
p<0.001 at 3 hr); no significant difference 
in blood glucose levels was observed at 30 
min post treatment (Figure 5). In the presence 
of orally co-administered pentamidine (Group 
3), metformin-mediated decrease in 
circulating glucose levels was attenuated at 1 
and 3 hours post treatment compared to the 
control group (p<0.05). The average decrease 
in blood glucose levels was 50% in Group 2 and 33% in Group 3 versus Group 1. These 
data correspond with a 49% decrease in area under the effect (AUE) of metformin in 
Group 2 compared to Group 1 (p<0.05), and a 33% decrease in AUE in Group 3 versus 
Group 1 which was not statistically significant (Figure 6). 
 
Discussion 
 Collectively, the data suggest that intestinal cation-selective transporters facilitate 
the glucose-lowering effect of oral metformin.  The trend toward a decrease in metformin 
glucose-lowering efficacy in the presence of the orally co-administered pan cation 
transporter inhibitor, pentamidine, implicates cation-selective transporters in the 
intestinal pharmacodynamic effects of metformin.  The trend in reduced efficacy is 
consistent with previously reported pharmacokinetic data on co-administered metformin 
and pentamidine, which showed reduced plasma concentrations of metformin as 
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compared to metformin being given alone.7 Even though the plasma concentration of 
metformin is significantly reduced with co-administration of pentamidine, the reduction is 
not enough to cause a statistically difference in the pharmacological effect of metformin.   
 Several limitations in the experiment could have contributed to the lack of 
statistical significance between metformin glucose-lowering efficacy in presence and 
absence of pentamidine.  The first limitation was the glucometer used in the study.  The 
OneTouch Ultra glucometer was only capable of reading blood glucose levels up to 600 
mg/dL.  If a mouse had a blood glucose level greater than 600 mg/dL, the exact level 
could not be determined.  Over the course of the study this error occurred infrequently, 
but it might have made the difference between significant and non-significant results.  
 A second limitation of the study was the wide variability in blood glucose levels of 
the mice. One factor that effected blood glucose levels was induced stress the mice 
experienced.  Stress could have occurred during different aspects of handling the mice.  
While administering the treatments, if oral gavage had to be attempted multiple times on 
the same mouse, there could have been an increase in stress levels which could have 
led to increased glucose release.  The same issue might have occurred when sampling 
blood via tail nicks.  Some mice had difficulties with bloodletting, which may have led to 
more stress.  The induced stress resulted in elevated blood glucose levels, which can be 
seen by the spikes in blood glucose within the first 30 minutes of each mouse.  There 
was inter-variability in blood glucose elevation between mice and could not be controlled 
for.  The amount of variability in blood glucose levels was not taken into consideration 
when determining the number of mice per treatment arm.  If the sample size was 
increased, it could help minimize the influence the variability of blood glucose had on the 
results and may be able to show that the intestinal transporters do in fact play a 
significant role in the glucose-lowering effect of metformin.  
 In conclusion, the data from this experiment show a trend that the intestinal 
cation-selective transporters play a role in the pharmacological effect of metformin.  
Genetic polymorphisms in these transporters could contribute to variability in metformin 
bioavailability in humans (40 to 60%), and in response to metformin therapy in T2DM.  
This study may help to facilitate future conversations as to why certain patients do not 
respond to metformin therapy, and even help researchers uncover foods or drugs that 
interact with metformin through use of these intestinal specific transporters.  
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